The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance

  • Sunil K. Joshi
  • , Tamilla Nechiporuk
  • , Daniel Bottomly
  • , Paul D. Piehowski
  • , Julie A. Reisz
  • , Janét Pittsenbarger
  • , Andy Kaempf
  • , Sara J.C. Gosline
  • , Yi Ting Wang
  • , Joshua R. Hansen
  • , Marina A. Gritsenko
  • , Chelsea Hutchinson
  • , Karl K. Weitz
  • , Jamie Moon
  • , Francesca Cendali
  • , Thomas L. Fillmore
  • , Chia Feng Tsai
  • , Athena A. Schepmoes
  • , Tujin Shi
  • , Osama A. Arshad
  • Jason E. McDermott, Ozgun Babur, Kevin Watanabe-Smith, Emek Demir, Angelo D'Alessandro, Tao Liu, Cristina E. Tognon, Jeffrey W. Tyner, Shannon K. McWeeney, Karin D. Rodland, Brian J. Druker, Elie Traer

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)999-1014.e8
JournalCancer Cell
Volume39
Issue number7
DOIs
StatePublished - Jul 12 2021

ASJC Scopus Subject Areas

  • Oncology
  • Cancer Research

Keywords

  • AML
  • Aurora kinase B
  • drug resistance
  • FLT3
  • gilteritinib
  • lipid metabolism
  • NRAS
  • quizartinib
  • tumor microenvironment
  • tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance'. Together they form a unique fingerprint.

Cite this